(Q34484276)

2 August 2017

1 reference

title

Pharmacological treatment for generalized anxiety disorder in adults: an update (English)

1 reference

generalized anxiety disorder

2 August 2017

1 reference

1 reference

Jennifer A Reinhold

1

1 reference

PubMed ID

26159446

2 August 2017

Karl Rickels

series ordinal

2

1 reference

PubMed ID

26159446

2 August 2017

language of work or name

English

0 references

publication date

1 August 2015

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

1 reference

2 August 2017

16

1 reference

2 August 2017

11

1 reference

2 August 2017

1669-1681

1 reference

Pharmacological treatment of generalized anxiety disorder

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

The intolerance of uncertainty construct in the context of anxiety disorders: theoretical and practical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: a study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Anxiety disorders in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Generalized anxiety disorder: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Role of pregabalin in the treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

The pharmacologic treatment of anxiety disorders: a review of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Efficacy of sertraline in a 12-week trial for generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Prevention of relapse in generalized anxiety disorder by escitalopram treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Drug therapy. Current status of benzodiazepines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Benzodiazepines: risks and benefits. A reconsideration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

The reappraisal of benzodiazepines in the treatment of anxiety and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Long-term Treatment of Anxiety and Risk of Withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Benzodiazepine use in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Effects of long-term administration of buspirone and diazepam on driver steering control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Long-term efficacy of pregabalin in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Pregabalin in generalized anxiety disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Effects of antipsychotic medications on appetite, weight, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Acute hyperglycemia associated with short-term use of atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

QTc prolongation, torsades de pointes, and psychotropic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

QT alterations in psychopharmacology: proven candidates and suspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Clomacran in anxious neurotic outpatients: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

Loxapine in Neurotic Anxiety: Some Modifiers of Treatment Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1059424

10.1517/14656566.2015.1059424

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

26159446